<DOC>
	<DOCNO>NCT01691235</DOCNO>
	<brief_summary>Subjects ask participate study genotype 1 Hepatitis C Virus ( HCV ) take standard care drug pegylated interferon , ribavirin , telaprevir part routine care . The purpose study see SIMpill automate pill dispense device help subject take medication time doctor instructed take . The SIMpill device automate pill dispense device record time stamp time device open dose medication take . Physicians download data generate precise account take medication . In addition , dose miss , SIMpill device set automatically notify text message dose overdue . The Simpill device new way keep track take HCV medication also help remind forget take dose . In addition , information help doctor understand take medication time effect success therapy .</brief_summary>
	<brief_title>SIMpill Medication Dispensing Device Treatment HCV</brief_title>
	<detailed_description>- Patients genotype 1 HCV candidate therapy telaprevir , pegylated interferon ribavirin eligible study . - All patient enrol study receive standard care regimen telaprevir /pegylated interferon ribavirin . This include medication dosage , follow-up , monitoring . The exception mode medication dispense . - Patients ask bring Simpill device regularly schedule clinic visit time medication adherence information download study personnel . Each visit regularly schedule standard care visit additional clinic visit need patient Simpill study arm . - In event patient demonstrate viral breakthrough therapy , patient offer additional blood draw screen viral resistance . This important understand patient use Simpill device well adherence medication regiment result low incidence viral resistance . - Patients study arm receive text message time dose medication miss . This message go telephone number specify patient go member study team . Patients text message capability eligible study . - The initial study pilot study design obtain preliminary data regard feasibility device . This study power detect difference viral kinetics first 4 week . - In event Vertex receive FDA approval BID dosage telaprevir prior fund initiation study , currently approve dosing ( BID ) use instead q8 hour .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Patients age 18 70 genotype 1 HCV Compensated liver disease independently deem appropriate candidate telaprevir contain HCV treatment regimen Prior liver transplantation Coinfection type viral hepatitis HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>SIMpill</keyword>
	<keyword>HCV</keyword>
	<keyword>Chronic Hepatitis C Virus</keyword>
</DOC>